Morphologic and molecular prognostic markers in prostate cancer
In this review, a series of traditional morphology-based measurements, relatively well-documented ancillary biomarkers, and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and are classif...
Gespeichert in:
| Veröffentlicht in: | Advances in anatomic pathology 2002-03, Vol.9 (2), p.115-128 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 128 |
|---|---|
| container_issue | 2 |
| container_start_page | 115 |
| container_title | Advances in anatomic pathology |
| container_volume | 9 |
| creator | Ross, Jeffrey S Sheehan, Christine E Dolen, Eric M Kallakury, Bhaskar V S |
| description | In this review, a series of traditional morphology-based measurements, relatively well-documented ancillary biomarkers, and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and are classified as category I by the College of American Pathologists' Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or in clinical trials (category III). |
| doi_str_mv | 10.1097/00125480-200203000-00003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71541454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71541454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-a4a8d0133d9fe92bd2fa86d2abe2e41eb099c5099190493ed8039318d707b6293</originalsourceid><addsrcrecordid>eNpFkE1PwzAMhnMAsTH4C6gnbgU7ST9yQmiCgTTEBc5Rmrij0I-RtAf-PRkbcLAt2a_9Wg9jCcIVgiquAZBnsoSUA3AQAJDGAHHE5ggFT2VUzdhpCO87ZZHjCZshKiwwz-bs5mnw27ehHTaNTUzvkm5oyU6t8cnWD5t-CGMcdMZ_kA9J0--6YTQjJdb0lvwZO65NG-j8UBfs9f7uZfmQrp9Xj8vbdWoF4pgaaUoHKIRTNSleOV6bMnfcVMRJIlWglM1iQgVSCXIlCCWwdAUUVc6VWLDL_d3o_zlRGHXXBEtta3oapqALzCTKTEZhuRfa-GjwVOutb-L_XxpB74DpX2D6D5j-ARZXLw4eU9WR-1880BLf6-dnsw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71541454</pqid></control><display><type>article</type><title>Morphologic and molecular prognostic markers in prostate cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Ross, Jeffrey S ; Sheehan, Christine E ; Dolen, Eric M ; Kallakury, Bhaskar V S</creator><creatorcontrib>Ross, Jeffrey S ; Sheehan, Christine E ; Dolen, Eric M ; Kallakury, Bhaskar V S</creatorcontrib><description>In this review, a series of traditional morphology-based measurements, relatively well-documented ancillary biomarkers, and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and are classified as category I by the College of American Pathologists' Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or in clinical trials (category III).</description><identifier>ISSN: 1072-4109</identifier><identifier>DOI: 10.1097/00125480-200203000-00003</identifier><identifier>PMID: 11917165</identifier><language>eng</language><publisher>United States</publisher><subject>Biomarkers, Tumor - analysis ; Carcinoma - diagnosis ; Carcinoma - genetics ; Carcinoma - pathology ; Cell Cycle Proteins - analysis ; Humans ; Male ; Neoplasm Invasiveness ; Neoplasm Proteins - analysis ; Neoplasm Staging ; Prognosis ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - pathology</subject><ispartof>Advances in anatomic pathology, 2002-03, Vol.9 (2), p.115-128</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-a4a8d0133d9fe92bd2fa86d2abe2e41eb099c5099190493ed8039318d707b6293</citedby><cites>FETCH-LOGICAL-c311t-a4a8d0133d9fe92bd2fa86d2abe2e41eb099c5099190493ed8039318d707b6293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11917165$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ross, Jeffrey S</creatorcontrib><creatorcontrib>Sheehan, Christine E</creatorcontrib><creatorcontrib>Dolen, Eric M</creatorcontrib><creatorcontrib>Kallakury, Bhaskar V S</creatorcontrib><title>Morphologic and molecular prognostic markers in prostate cancer</title><title>Advances in anatomic pathology</title><addtitle>Adv Anat Pathol</addtitle><description>In this review, a series of traditional morphology-based measurements, relatively well-documented ancillary biomarkers, and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and are classified as category I by the College of American Pathologists' Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or in clinical trials (category III).</description><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - pathology</subject><subject>Cell Cycle Proteins - analysis</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Proteins - analysis</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - pathology</subject><issn>1072-4109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1PwzAMhnMAsTH4C6gnbgU7ST9yQmiCgTTEBc5Rmrij0I-RtAf-PRkbcLAt2a_9Wg9jCcIVgiquAZBnsoSUA3AQAJDGAHHE5ggFT2VUzdhpCO87ZZHjCZshKiwwz-bs5mnw27ehHTaNTUzvkm5oyU6t8cnWD5t-CGMcdMZ_kA9J0--6YTQjJdb0lvwZO65NG-j8UBfs9f7uZfmQrp9Xj8vbdWoF4pgaaUoHKIRTNSleOV6bMnfcVMRJIlWglM1iQgVSCXIlCCWwdAUUVc6VWLDL_d3o_zlRGHXXBEtta3oapqALzCTKTEZhuRfa-GjwVOutb-L_XxpB74DpX2D6D5j-ARZXLw4eU9WR-1880BLf6-dnsw</recordid><startdate>200203</startdate><enddate>200203</enddate><creator>Ross, Jeffrey S</creator><creator>Sheehan, Christine E</creator><creator>Dolen, Eric M</creator><creator>Kallakury, Bhaskar V S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200203</creationdate><title>Morphologic and molecular prognostic markers in prostate cancer</title><author>Ross, Jeffrey S ; Sheehan, Christine E ; Dolen, Eric M ; Kallakury, Bhaskar V S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-a4a8d0133d9fe92bd2fa86d2abe2e41eb099c5099190493ed8039318d707b6293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - pathology</topic><topic>Cell Cycle Proteins - analysis</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Proteins - analysis</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ross, Jeffrey S</creatorcontrib><creatorcontrib>Sheehan, Christine E</creatorcontrib><creatorcontrib>Dolen, Eric M</creatorcontrib><creatorcontrib>Kallakury, Bhaskar V S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in anatomic pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ross, Jeffrey S</au><au>Sheehan, Christine E</au><au>Dolen, Eric M</au><au>Kallakury, Bhaskar V S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Morphologic and molecular prognostic markers in prostate cancer</atitle><jtitle>Advances in anatomic pathology</jtitle><addtitle>Adv Anat Pathol</addtitle><date>2002-03</date><risdate>2002</risdate><volume>9</volume><issue>2</issue><spage>115</spage><epage>128</epage><pages>115-128</pages><issn>1072-4109</issn><abstract>In this review, a series of traditional morphology-based measurements, relatively well-documented ancillary biomarkers, and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and are classified as category I by the College of American Pathologists' Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or in clinical trials (category III).</abstract><cop>United States</cop><pmid>11917165</pmid><doi>10.1097/00125480-200203000-00003</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1072-4109 |
| ispartof | Advances in anatomic pathology, 2002-03, Vol.9 (2), p.115-128 |
| issn | 1072-4109 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71541454 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Biomarkers, Tumor - analysis Carcinoma - diagnosis Carcinoma - genetics Carcinoma - pathology Cell Cycle Proteins - analysis Humans Male Neoplasm Invasiveness Neoplasm Proteins - analysis Neoplasm Staging Prognosis Prostatic Neoplasms - diagnosis Prostatic Neoplasms - genetics Prostatic Neoplasms - pathology |
| title | Morphologic and molecular prognostic markers in prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Morphologic%20and%20molecular%20prognostic%20markers%20in%20prostate%20cancer&rft.jtitle=Advances%20in%20anatomic%20pathology&rft.au=Ross,%20Jeffrey%20S&rft.date=2002-03&rft.volume=9&rft.issue=2&rft.spage=115&rft.epage=128&rft.pages=115-128&rft.issn=1072-4109&rft_id=info:doi/10.1097/00125480-200203000-00003&rft_dat=%3Cproquest_cross%3E71541454%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71541454&rft_id=info:pmid/11917165&rfr_iscdi=true |